Le Lézard
Classified in: Health
Subject: FDA

TVA Medical Receives FDA De Novo Marketing Authorization For everlinQ® endoAVF System


AUSTIN, Texas, June 22, 2018 /PRNewswire/ -- TVA Medical, Inc. today announced it has received U.S. Food and Drug Administration (FDA) De Novo marketing authorization of the everlinQ® endoAVF System. This innovative, minimally invasive technology uses magnetic catheters and radiofrequency energy to create an arteriovenous fistula (AVF) for hemodialysis access without open surgery.

TVA Medical's everlinQ(R) endoAVF System catheters, now with FDA marketing authorization for use in the U.S.

"The everlinQ endoAVF System is a significant advance in the management of chronic kidney disease," said Paul Kreienberg, M.D., vascular surgeon at The Vascular Group, Albany Medical College, Albany Medical Center Hospital, Albany, N.Y. "Hundreds of thousands of Americans require vascular access for lifesaving dialysis, but until now this access has required open surgery that is accompanied by high failure rates and low patient satisfaction. The everlinQ endoAVF System is transforming vascular access using a minimally invasive approach, and I anticipate a high level of interest from both patients and physicians for this compelling endovascular solution."

More than 400,000 people in the U.S. receive hemodialysis multiple times a week for end-stage renal disease (ESRD)1. The current standard vascular access approach uses open surgery to create an AVF for dialysis. Surgical AVFs are associated with failure rates up to 60 percent2 and often require frequent revisions.3,4 When a surgical AVF procedure is effective, the fistula takes on average over four months to mature before dialysis can begin.1 In addition, vascular access creates concern and stress for many ESRD patients, including the threat of repeat procedures and disfigurement of the arm, with up to 30 percent of patients refusing fistula surgery.5

"Vascular access issues significantly hinder the delivery of adequate dialysis for patients, and there has been little innovation related to surgical fistula creation in more than 50 years," added Dr. Kreienberg. "The everlinQ endoAVF System is a significant new vascular access option for these patients."

The FDA marketing authorization enables use of the everlinQ endoAVF System as a Class II medical device in the ulnar artery and ulnar vein, to create an endoAVF for hemodialysis use in properly indicated patients. Data from four clinical studies using the everlinQ endoAVF System demonstrated 97 percent procedural success; 88 percent fistula maturation (suitable for dialysis) at three months; and 75 percent successful cannulation at six months with minimal need for re-intervention.

"FDA marketing authorization of the everlinQ endoAVF System is a monumental milestone for dialysis patients who now have an alternative AVF option," said Adam L. Berman, president and CEO of TVA Medical. "Thanks to extensive collaboration with the FDA, clinical study investigators and clinical advisors, we are thrilled to now partner with the U.S. vascular surgery and nephrology communities to offer an innovative endovascular fistula creation approach. Training will begin immediately at select U.S. vascular surgery centers, and a U.S. post-market study is scheduled to initiate before the end of the year."

The everlinQ endoAVF System was reviewed by the FDA through the De Novo premarket review pathway, a regulatory process for some new medical devices that are low to moderate risk and have no legally marketed predicate device to base a determination of substantial equivalence. The everlinQ endoAVF System received European CE Mark in 2014 and Health Canada Medical Device License in 2016 for ESRD patients.

About the everlinQ endoAVF System
The everlinQ endoAVF System is designed to create an AVF for hemodialysis access using an endovascular approach. In the procedure, two flexible magnetic catheters are inserted into an artery and vein in the arm. A small amount of radiofrequency energy is used to connect the artery and vein to create the fistula. The catheters are then removed and a brachial vein is coil-embolized, enabling future dialysis.

About TVA Medical
TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease and other potential applications, such as peripheral vascular disease. Please visit www.TVAMedical.com, https://twitter.com/TVAMed and https://www.linkedin.com/company/tva-medical-inc./ for more information.

1 United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2017.
2 Al-jaishi, A. et al.  Patency Rates of the Arteriovenous Fistula for Hemodialysis: A Systematic Review and Meta-
3 Lok, C. Fistula First Initiative: Advantages and Pitfalls.Clin J Am Soc Nephrol 2: 1043-1053, 2007.
4 Falk A. Maintenance and salvage of arteriovenous fistulas. J Vasc Interv Radiol. 2006;17(5):807-13
5 Casey, Jordan R. et al. Patients' Perspectives on Hemodialysis Vascular Access: A Systematic Review of Qualitative Studies. Am J Kidney Dis 2014; 64:937-53.

 

TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease, including a catheter-based AV fistula system. More information is available at www.TVAMedical.com. (PRNewsFoto/TVA Medical, Inc.)

SOURCE TVA Medical, Inc.


These press releases may also interest you

at 14:30
The "Global Immunoprecipitation Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Global Immunoprecipitation Testing Market size is estimated...

at 14:25
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...

at 14:20
Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its...

at 14:12
Susan G. Komen®, the world's leading breast cancer organization commends the State Assembly's proposed funding increase of $2.5 million for the Cancer Services Program (CSP) in the FY2025 Budget....

at 14:00
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night. Now, a new study proposes a mechanism that determines which memories are...

at 14:00
While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which...



News published on and distributed by: